Article info
PDFReview
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
- Correspondence to Dr Zhihong Lai; zhihong.v.lai{at}gsk.com and Dr Anna La Noce; anna.lanoce{at}wwctrials.com
Citation
Key design considerations on comparative clinical efficacy studies for biosimilars: adalimumab as an example
Publication history
- Received July 16, 2015
- Revision received December 12, 2015
- Accepted December 19, 2015
- First published February 7, 2016.
Online issue publication
July 18, 2023
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/ This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/